BCRX — BIOCRYST PHARMACEUTICALS INC

—
Nasdaq · Health Care · Biotechnology · CIK 882796 ·
Last close
$7.50
Market Cap
$1.93B
52W High
$11.22
52W Low
$6.23
ADV30
5,237,027
Next earnings
2026-11-04

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 180,292,000 178,718,000 53,330,000 37,916,000 591,070,000 96,971,000 988,454,000
Jun 2026 218,250,000 214,410,000 98,465,000 78,395,000 557,851,000 154,972,000 1,012,140,000
Mar 2026 156,413,000 151,036,000 -701,598,000 -721,812,000 465,052,000 171,591,000 1,018,895,000
Dec 2025 406,555,000 397,033,000 260,385,000 245,845,000 514,158,000 89,736,000 633,311,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$367,494,000
Investing CF
$-541,159,000
Financing CF
$171,363,000
CapEx
$-1,647,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.42
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-2,111,680,000
Inventory
$13,740,000
Receivables
$121,786,000
ST Investments
$278,027,000
EBIT TTM
$-277,921,000
Pretax Income TTM
$-354,732,000
Interest Exp TTM
$76,811,000
Analysts
11

Yahoo Snapshot (yfinance, live)

Total Revenue
$961,510,016
EBITDA
$472,468,000
Free Cash Flow
$301,088,256
Enterprise Value
$2,431,832,320
Total Cash
$374,998,016
Total Debt
$828,198,976
Shares Out
257,299,269
Trailing EPS
$-1.28
Book Value
$-1.55
ROE
—
ROA
56.5%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 874,837,000 340,989,000 263,861,000 514,158,000 633,311,000 -119,153,000 347,369,000
Dec 2024 450,712,000 -2,543,000 -88,881,000 490,420,000 966,354,000 -475,934,000 -52,020,000
Dec 2023 331,412,000 -103,709,000 -226,539,000 516,960,000 972,488,000 -455,528,000 -95,141,000
Dec 2022 270,827,000 -148,435,000 -247,116,000 550,000,000 844,597,000 -294,597,000 -161,850,000

TTM Snapshot

Revenues TTM
$940,613,000
NetIncome TTM
$-384,673,000
OpCashFlow TTM
—
Assets (Latest)
$557,851,000
Forward EPS
$0.82

Max Pain — expiry 2026-12-18

max pain strike: $8.00 · spot: $7.30 · call oi: 6,230 · put oi: 1,186
Expected Move to 2026-12-18: ±$0.92 (12.60%) — implied range $6.38 – $8.22 · ATM straddle on $7.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
REPL Replimune Group, Inc. $1.87B $19.69 —
COAG Hemab Therapeutics Holdings, Inc. $1.83B $39.06 —
MAZE Maze Therapeutics, Inc. $1.80B $32.87 —
BEAM Beam Therapeutics Inc. $2.14B $20.65 —
RXRX RECURSION PHARMACEUTICALS, INC. $1.69B $2.72 —

News headlines (Yahoo Finance, 1h cache)

BioCryst Presents New Real-World Evidence Showing Reduced Angioedema-Related Medical Visits After Switching to ORLADEYO® (berotralstat) at ACAAI 2026 Annual Scientific Meeting
2026-11-13 12:00 · Yahoo
The Zacks Analyst Blog Highlights TG Therapeutics, BioCryst, Insmed and Madrigal
2026-11-11 06:36 · Yahoo
BioCryst Pharmaceuticals (BCRX) Raised Its Outlook, Is It Still Below Fair Value?
2026-11-07 07:11 · Yahoo
BioCryst Pharmaceuticals Inc (BCRX) (Q3 2026) Earnings Call Highlights: ORLADEYO Revenue Climbs ...
2026-11-05 09:07 · Yahoo
BioCryst to Present at Upcoming Investor Conferences
2026-11-04 21:01 · Yahoo
BioCryst (BCRX) Q3 2026 Earnings Call Transcript
2026-11-04 17:30 · Yahoo
BioCryst Pharmaceuticals Q3 Earnings Call Highlights
2026-11-04 16:14 · Yahoo
BioCryst Pharmaceuticals (BCRX) Surpasses Q3 Earnings and Revenue Estimates
2026-11-04 12:55 · Yahoo
BioCryst: Q3 Earnings Snapshot
2026-11-04 12:22 · Yahoo
BioCryst Reports Third Quarter 2026 Financial Results
2026-11-04 12:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.